Vaccine-educated T cells and a CD123 bispecific T-cell engager for treatment of acute myeloid leukemia.

ABSTRACT:

Abstract

T-cell engager (TCE) therapy has demonstrated significant therapeutic efficacy in patients with hematologic malignancies. Durable responses have been linked with T-cell clonotypic expansion. We hypothesized that combining vaccine-educated T cells (veTcs) that induce the expansion of leukemia-specific T cells would enhance efficacy of TCE through greater induction of tumor-specific immunity. In this study, we explored a TCE targeting human CD123 on myeloid leukemia cells in conjunction with T cells stimulated by an autologous dendritic cell/acute myeloid leukemia fusion vaccine in a murine xenograft model. We demonstrated that the combination of CD123 TCE (SAR440234) and veTcs boosted tumor-specific T-cell immunity and enhanced antileukemia effect in vitro. Furthermore, in

SUBMITTER: Liegel J 

PROVIDER: S-EPMC12630361 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature